TABLE 5.
Summary of the comparative results with the 279-serum premarketing panel from the CDC
| Sera | Antibody | % LD positive (no. positive/total) |
|
|---|---|---|---|
| DbpA/C6-OspCa | 2-tier method | ||
| Stage I LD | IgG | 78 (46/59)b | 29 (17/59) |
| IgM | 64 (38/59)c | 51 (30/59) | |
| IgG/IgM | 80 (47/59)a | 63 (37/59) | |
| Stage II and III LD | IgG | 97 (29/30)c | 87 (26/30) |
| IgM | 43 (13/30)c | 53 (16/30) | |
| IgG/IgM | 100 (30/30)c | 100 (30/30) | |
| LD-negative subjects | IgG | 0 (0/160)c | 0 (0/160) |
| IgM | 1 (2/160)c | 0 (0/160) | |
a
DbpA/C6 for detecting IgG and OspC for detecting IgM.
b
Statistically superior (see Table S2 in the supplemental material).
c
No statistical difference (see Table S2 in the supplemental material).